PT-141 (Bremelanotide) Global Regulatory Status

HealthRX.com

Bremelanotide is FDA-approved as Vyleesi, not compounded PT-141

Print or save as PDF

Key numbers

  • 1.75 mgDose of the prescription-only Vyleesi subcutaneous autoinjectorSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 24 weeksTreatment duration of the phase 3 trials of bremelanotide or placebo in premenopausal womenSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 8 doses per monthMaximum monthly Vyleesi doses the label does not recommend exceedingSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

From the public record

Patents and generic approvals for bremelanotide

The FDA Orange Book lists 0 approved generic applications for bremelanotide across 1 listed product. 4 listed patents have not yet expired, the last on 2041-04-29.

Patents and generic approvals for bremelanotide: the figures
MeasureValue
Brand-name applications (NDA)1
Approved generic applications (ANDA)0
Listed patents not yet expired4
Latest listed patent expiry2041-04-29
Earliest approval date on file2019-06-21
Products not marked discontinued1 of 1

Source: FDA, Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), data as of Oct 9, 2026

How this was calculated

Selected Orange Book products whose only active ingredient is this substance, then counted applications by type and the distinct patents and exclusivities listed against them. Expired patents are left out.

Scope: All single-ingredient bremelanotide products in the Orange Book, every brand and strength, files dated 2026-10-09

An approved generic or an expired patent does not show that a generic is on sale. Launch timing also depends on litigation, settlements and supply. Biologics and compounded products are not in the Orange Book.

Download the data (CSV)

From the public record

FDA approval history for bremelanotide

The earliest FDA approval on file for a bremelanotide product is 2019-06-21. Drugs@FDA lists 1 application for it and 2 approved supplements, the most recent on 2026-10-22.

FDA approval history for bremelanotide: the figures
MeasureValueNote
Earliest FDA approval on file2019-06-21
Applications with an approval on file1
New drug applications (NDA)1
Generic applications (ANDA)0
Approved supplements2label, manufacturing and efficacy changes
Most recent supplement approval2026-10-22
Sponsoring companies1

Source: FDA, Drugs@FDA, data as of Nov 11, 2026

How this was calculated

Selected applications with a product whose only active ingredient is this substance, then counted approved original and supplemental submissions. The earliest approved original submission is the first approval.

Scope: Applications with a single-ingredient bremelanotide product in Drugs@FDA, all sponsors and strengths

Older approvals can be missing dates, and tentative approvals are not counted. An approved application does not mean the product is currently marketed.

Download the data (CSV)

From the public record

FDA label facts for bremelanotide

The FDA label read for bremelanotide (Vyleesi, application NDA210557) was last revised on 2026-11-05. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.

FDA label facts for bremelanotide: the figures
MeasureValueNote
Label revision date2026-11-05
Label readVyleesiNDA210557, brand-name application
Boxed warningNo
Pregnancy sectionPresent
Lactation sectionPresent
Pediatric use sectionPresent
Geriatric use sectionPresent

Source: FDA drug label via openFDA, viewable on NIH DailyMed, data as of Nov 11, 2026

How this was calculated

Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.

Scope: One label: the newest prescription label for single-ingredient bremelanotide from an original manufacturer

Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.

Download the data (CSV)

At a glance

  • U.S. approval / Vyleesi, NDA 210557, June 21, 2019 [1][2]
  • Current NDA holder / Cosette Pharmaceuticals [2]
  • Approved population / Premenopausal women with acquired, generalized HSDD [1]
  • Not approved for / Postmenopausal women, men, or sexual performance enhancement [1]
  • Boxed warning / None in the Vyleesi label [1]
  • Compounded PT-141 / Not Vyleesi; not FDA-approved [3]
  • WADA 2026 Prohibited List / Not named [8]

What did the FDA approve?

Bremelanotide is FDA-approved as Vyleesi under NDA 210557, original approval June 21, 2019; Cosette Pharmaceuticals is the current holder, AMAG the original one [1][4][2]. It is prescription only, a 1.75 mg subcutaneous autoinjector [1].

The approved use is premenopausal women with acquired, generalized HSDD: low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says Vyleesi is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1]. The label carries no boxed warning, and the 2019 approval letter includes no REMS [1][4].

What trial data supported approval?

Two identical phase 3 trials randomized 1,267 premenopausal women with HSDD to bremelanotide 1.75 mg or placebo for 24 weeks; 1,247 were in the safety population and 1,202 in the modified intent-to-treat efficacy population [5][1]. Mean change from baseline on the FSFI-desire domain was 0.5 with Vyleesi versus 0.2 with placebo in Study 1, and 0.6 versus 0.2 in Study 2 [1]. The trials did not show a significant difference in the number of satisfying sexual events [5].

What changed in the U.S. label in 2026?

On October 22, 2026, FDA approved a labeling supplement (S-005) that updates Section 8 (Use in Specific Populations) and the patient information [2][10]. The DailyMed label used for this page has an effective date of November 13, 2025, and does not yet show that new text.

What does the U.S. label say about use?

The approved Vyleesi regimen is 1.75 mg injected under the skin of the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity. The label limits use to one dose in 24 hours and does not recommend more than 8 doses per month [1]. The label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1].

What about compounded PT-141?

Compounded PT-141 is not Vyleesi, the FDA-approved bremelanotide product. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing [3]. Bremelanotide is not listed among FDA's bulk substances that may present significant safety risks when compounded, content dated April 22, 2026 [7]. It is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9].

Questions worth asking

Choose the questions you want to keep

Is bremelanotide on the WADA Prohibited List?

Bremelanotide is not named on WADA's 2026 Prohibited List [8]. Because it is FDA-approved, WADA's S0 class for substances with no approval from any governmental health authority does not cover it by definition [8].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the label, when should Vyleesi be injected before anticipated sexual activity?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

Is PT-141 the same as Vyleesi?
Vyleesi is the FDA-approved bremelanotide product [2]. Compounded PT-141 is not Vyleesi and is not FDA-approved [3].
What is Vyleesi approved to treat?
Premenopausal women with acquired, generalized HSDD. It is not indicated for postmenopausal women, for men, or to enhance sexual performance [1].
What dose does the Vyleesi label specify?
The label specifies 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. It does not recommend more than 8 doses per month [1].
Is bremelanotide on the WADA Prohibited List?
Bremelanotide is not named on WADA's 2026 Prohibited List [8].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is PT-141 FDA approved?

Yes. Bremelanotide is FDA-approved as Vyleesi under NDA 210557 for premenopausal women with acquired, generalized HSDD. Compounded PT-141 is not Vyleesi and is not an FDA-approved drug. Vyleesi is prescription only and comes as a 1.75 mg subcutaneous autoinjector.

Where can I buy bremelanotide PT-141?

No sellers or sources are named. Vyleesi is prescription only, given as a 1.75 mg subcutaneous autoinjector. Compounded PT-141 is not Vyleesi and is not FDA-approved, and FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

References

Show all 10 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. Drugs@FDA: FDA-Approved Drugs.
  3. Compounding and the FDA: Questions and Answers | FDA.
  4. U.S. Food and Drug Administration.
  5. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
  6. Medicines | European Medicines Agency (EMA).
  7. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  8. World Anti-Doping Agency.
  9. U.S. Department of Health and Human Services. HHS 503A peptide enforcement discretion policy, Appendix B. HHS peptide enforcement discretion policy appendix B
  10. U.S. Food and Drug Administration. NDA 210557 supplement 5 approval letter, October 22, 2026.
Evidence overview for PT-141 (Bremelanotide) Global Regulatory Status